Nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) gene mutation test results before starting treatment, according to a new survey of oncologists in 10 countries.
National Guideline Clearinghouse | Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline.
HER2 stands for human epidermal growth factor receptor 2 and is most often seen as HER2. It's a cell protein that stimulates cancer cells to grow. Its presence usually indicates an aggressive cancer. (Click the picture to read more.)
#LungCancer #NonSmallCellLungCancer #CancerResearch With the new cobas Epidermal Growth Factor Receptor test, doctors at some public hospitals are now able to detect the presence of gene mutations. About half of non-small cell lung cancer is linked to a genetic epidermal growth factor receptor (EGFR) mutation - affecting mostly female non-smokers.
The U.S. Food and Drug Administration approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.